Cargando…

Lung toxicity of lomustine in the treatment of progressive gliomas

BACKGROUND: Pulmonary fibrosis is a rare, but dangerous side effect of CCNU (lomustine). CCNU is a frequently used chemotherapeutic agent in the setting of recurrent or progressive glioblastoma. At present, CCNU is also administered in patients with newly diagnosed gliomas in combination with temozo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seliger, Corinna, Nürnberg, Christina, Wick, Wolfgang, Wick, Antje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155160/ https://www.ncbi.nlm.nih.gov/pubmed/35664555 http://dx.doi.org/10.1093/noajnl/vdac068

Ejemplares similares

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review
por: Irfan, Nabia, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
por: Coomans, Marijke B, et al.
Publicado: (2022)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Current usage of tumor treating fields for glioblastoma
por: Lassman, Andrew B, et al.
Publicado: (2020)

Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor
por: Radhakrishnan, Venkatraman, et al.
Publicado: (2017)

Treatment of glioblastoma in adults
por: Wick, Wolfgang, et al.
Publicado: (2018)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Conventional and emerging treatments of astrocytomas and oligodendrogliomas
por: Kessler, Tobias, et al.
Publicado: (2022)

Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
por: Coomans, Marijke B, et al.
Publicado: (2019)

Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro
por: Fuchs, Daniel, et al.
Publicado: (2023)

Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma
por: Leone, Riccardo, et al.
Publicado: (2023)

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
por: Wick, Wolfgang, et al.
Publicado: (2019)

Clinical feasibility of modified procarbazine and lomustine chemotherapy without vincristine as a salvage treatment for recurrent adult glioma
por: Ahn, Stephen, et al.
Publicado: (2022)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
por: Beije, N, et al.
Publicado: (2015)

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
por: Berghoff, Anna Sophie, et al.
Publicado: (2020)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
por: Larkin, J M G, et al.
Publicado: (2007)

Longitudinal MR spectroscopy to detect progression in patients with lower-grade glioma in the surveillance phase
por: Avalos, Lauro N, et al.
Publicado: (2022)

Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma
por: Smallwood, Katherine, et al.
Publicado: (2020)

Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma
por: Li, Xianqi, et al.
Publicado: (2022)

Diffusion basis spectrum imaging as an adjunct to conventional MRI leads to earlier diagnosis of high-grade glioma tumor progression versus treatment effect
por: Han, Rowland H, et al.
Publicado: (2023)

Automated detection and quantification of brain metastases on clinical MRI data using artificial neural networks
por: Pflüger, Irada, et al.
Publicado: (2022)

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
por: Grassl, Niklas, et al.
Publicado: (2023)

Lomustine’s nanoemulsion as nose-to-brain drug delivery system for CNS tumor treatment
por: Alaayedi, Maryam H., et al.
Publicado: (2023)

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
por: Friedrich, Mirco, et al.
Publicado: (2022)

Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding
por: Shamash, J, et al.
Publicado: (2005)

Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning
por: Pisapia, Jared M, et al.
Publicado: (2020)

Genetically Modified Cellular Therapies for Malignant Gliomas
por: Kilian, Michael, et al.
Publicado: (2021)

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
por: Blobner, Jens, et al.
Publicado: (2021)

Drug Repurposing of Metabolic Agents in Malignant Glioma
por: Seliger, Corinna, et al.
Publicado: (2018)

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
por: Tesileanu, C Mircea S, et al.
Publicado: (2021)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
por: Bunse, Lukas, et al.
Publicado: (2022)

Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?
por: Burth, Sina, et al.
Publicado: (2021)

Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment
por: Tsai, Jessica W, et al.
Publicado: (2022)

Toward unraveling the correlates of fatigue in glioma
por: Röttgering, Jantine G, et al.
Publicado: (2022)

Leptomeningeal disease in histone-mutant gliomas
por: Diaz, Maria, et al.
Publicado: (2023)

Physician Satisfaction With Lactation Resources Following an Intervention to Improve Lactation Accommodations
por: Mourad, Michelle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ju65ivr8sna8kec8eog327fm54